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Purpose. We evaluated the cost-effectiveness of adjuvant
chemotherapy using 5-fluorouracil, leucovorin (5FU/LV),
and oxaliplatin (FOLFOX) compared with 5FU/LV alone
and 5FU/LV compared with observation alone for patients
who had resected stage II colon cancer. Methods. We
developed 2 Markov models to represent the adjuvant che-
motherapy and follow-up periods and a single Markov
model to represent the observation group. We used calibra-
tion to estimate the transition probabilities among different
toxicity levels. The base case considered 60-year-old pa-
tients who had undergone an uncomplicated hemicolec-
tomy for stage II colon cancer and were medically fit to
receive 6 months of adjuvant chemotherapy. We measured
health outcomes in quality-adjusted life-years (QALYs) and
estimated costs using 2007 US dollars. Results. In the base
case, adjuvant chemotherapy of the FOLFOX regimen had
an incremental cost-effectiveness ratio (ICER) of $54,359/
QALY compared with the 5FU/LV regimen, and the 5FU/
LV regimen had an ICER of $14,584/QALY compared
with the observation group from the third-party payer per-
spective. The ICER values were most sensitive to 5-year
relapse probability, cost of adjuvant chemotherapy, and
the discount rate for the FOLFOX arm, whereas the ICER
value of 5FU/LV was most sensitive to the 5-year relapse
probability, 5-year survival probability, and the relapse
cost. The probabilistic sensitivity analysis indicates that
the ICER of 5FU/LV is less than $50,000/QALY with
a probability of 99.62%, and the ICER of FOLFOX as
compared with 5FU/LV is less than $50,000/QALY and
$100,000/QALY with a probability of 44.48% and
97.24%, respectively. Conclusion. Although adjuvant
chemotherapy with 5FU/LV is cost-effective at all ages
for patients who have undergone an uncomplicated hem-
icolectomy for stage II colon cancer, FOLFOX is not likely
to be cost-effective as compared with 5FU/LV. Key
words: colon cancer; stage II; cost-effectiveness; Markov
model; calibration. (Med Decis Making 2013;33:521–
532)
In 2012, 143,000 new cases of colorectal cancerwere estimated.1 Behind lung cancer, colorectal
cancer is the second-leading cause of cancer
death.2,3 Survival rates over the past 2 decades have
improved, primarily due to advances in screening,
diagnosis, and treatment. For example, the introduc-
tion of 5-fluorouracil (5FU)–based adjuvant chemo-
therapy in the late 1980s reaped a 30% mortality
reduction for stage III colon cancer.2 Since 1990,
5FU-based adjuvant chemotherapy has been
acknowledged as the standard of care for stage III
colon cancer. The FOLFOX regimen (oxaliplatin,
5FU, and leucovorin) has been established as
a widely accepted standard for adjuvant therapy in
stage III colon cancer based on the Multicenter Inter-
national Study of Oxaliplatin/5-Fluorouracil/Leu-
covorin in the Adjuvant Treatment of Colon Cancer
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(MOSAIC) trial since its publication in 2004.4 The
cost-effectiveness of adjuvant FOLFOX compared
with 5FU/LV (5FU and leucovorin) in the stage III
setting has been analyzed and described by Egging-
ton and colleagues,5 with an acceptable cost/qual-
ity-adjusted life year (QALY) of £2970 ($3800) for
the addition of oxaliplatin.
The benefit of 5FU/LV-based adjuvant chemother-
apy for unselected stage II colon cancer patients is
uncertain. To address this uncertainty, several stud-
ies have focused on estimating the magnitude of the
benefit. An earlier study included 1016 stage II
patients and found that the 5-year survival was 80%
for untreated patients and 82% for patients treated
with FU 1 leucovorin, where the survival difference
was not statistically significant.6 The QUick and Sim-
ple And Reliable (QUASAR) study conducted a large-
scale randomized trial on 3239 patients (91% with
stage II disease) to explore the effectiveness of adju-
vant chemotherapy for stage II colorectal cancer.7
This study found that 5-year survival without and
with adjuvant chemotherapy is 80% and 83.6%,
respectively. A recent study demonstrated the poten-
tial utility of adjuvant chemotherapy in stage II colon
cancer based on the data of 20,898 patients from 18
randomized trials. This study reported that 8-year
survival of patients undergoing adjuvant chemother-
apy improved from 66.8% to 72.2% (P = 0.026) when
compared with observation alone.8
There is also uncertainty around the risk/benefit of
adding oxaliplatin to 5FU for adjuvant treatment of
stage II colon cancer, which has been considered in
the MOSAIC study.9 The MOSAIC study suggests
an improvement from 84.3% to 87% of 3-year dis-
ease-free survival in stage II colon cancer patients
with the addition of oxaliplatin to 5FU/LV treatment:
a small, albeit consistent survival benefit. However,
the benefit up to this point has been too small to merit
the widespread use of adjuvant chemotherapy for
stage II colon cancer.
Overall, although these studies found a small ben-
efit in overall survival with adjuvant chemotherapy
for both 5FU/LV and FOLFOX in stage II colon can-
cer,10 it is still not clear whether this small gain out-
weighs the additional burden of this treatment due
to cost and toxicity.11 In the most recently updated
data of the MOSAIC trial, the benefit of FOLFOX
over 5FU/LV was small in stage II disease, and no
comparison was made to observation alone.12 There-
fore, adjuvant chemotherapy using 5FU/LV may have
a better incremental cost-effectiveness ratio (ICER)
for stage II colon cancer since it has similar efficacy
and is less costly than oxaliplatin-containing
regimens. The purpose of this study is to investigate
whether the use of FOLFOX as compared with 5FU/
LV and 5FU/LV as compared with observation is
cost-effective for patients who have had primary sur-
gery for stage II colon cancer.
METHODS
We constructed 2 Markov models to estimate the
incremental cost-effectiveness of treating postsurgery
patients who had stage II colon cancer with adjuvant
chemotherapy using FOLFOX compared with 5FU/
LV and those using 5FU/LV compared with no treat-
ment. We performed an analysis from the third-party
payer perspective, which includes only the direct med-
ical costs. We used QALYs to evaluate the effectiveness
of the treatments. We considered 60-year-old patients
with stage II colon cancer as our base case because of
the median ages of the 2 important data sources in
our research: QUASAR7 and MOSAIC.12 They had
undergone a hemicolectomy for stage II colon cancer,
recovered, and were medically fit to receive 6 months
of adjuvant FOLFOX or 5FU/LV chemotherapy. We
discounted costs and benefits by 3% per year.
Markov Models
We built 2 Markov models that represent the adju-
vant chemotherapy period and follow-up period for
patients who had stage II colon cancer, and the
same Markov model applies to both regimens with
different parameters. We individually simulated
5000 patients using the Markov models and imple-
mented the simulation in the JAVA programming
environment.
Adjuvant Chemotherapy Period Model. Our Mar-
kov model for the adjuvant chemotherapy period
consists of the following 5 states (Figure 1A): well
(state 1), minor toxicity (state 2), major toxicity (state
3), quitting adjuvant chemotherapy (state 4), and
death due to adjuvant chemotherapy (state 5). We
assumed that the transitions among those 5 states
were Markovian. Following the Common Toxicity
Criteria of the National Cancer Institute,13 version
3, we used 3 levels (well, minor toxicity, and major
toxicity) to represent the toxicity of adjuvant chemo-
therapy where ‘‘well’’ represents no toxicity (grade
0), ‘‘minor toxicity’’ represents mild or moderate
adverse effects (grade 1 and 2), and ‘‘major toxicity’’
represents severe or life-threatening adverse effects
(grade 3 and 4).14 We set the cycle length of the Mar-
kov model as 1 month—that is, the transitions occur
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on a monthly basis. The Markov model runs for 6
months. To have truly stage II disease, it would
have to be established with surgery and pathologic
analysis of the colon and lymph nodes. The surgery
that is performed is a hemicolectomy. We initialize
all patients to begin in state 1 (free of cancer) at
the start of the adjuvant chemotherapy since we
model the patients who had undergone an uncom-
plicated hemicolectomy for stage II colon cancer.
Follow-up Period Model. Patients without adjuvant
chemotherapy (observation group) move directly to
the follow-up period after the resection. Patients
who receive adjuvant chemotherapy (chemotherapy
groups) enter the follow-up period after the adjuvant
chemotherapy, which lasts for 6 months. We mod-
eled the follow-up period using the following 3
states (Figure 1B): free of cancer (state 1), alive
with relapse (state 2), and death (state 3). The total
follow-up time is 5 years. We set the cycle length
as 1 year for the observation group. On the other
hand, since the chemotherapy group undergoes
treatment for 6 months, we set the follow-up period
as 4.5 years, where the cycle length is 6 months for
the first cycle and 1 year for the subsequent cycles.
We apply annual transition probabilities for the ini-
tial 6-month cycle. Therefore, the overall duration
for the chemotherapy group is also 5 years.
Assumptions
Patients endure different grades of toxicity during
chemotherapy due to toxicity accumulation and
toxicity alleviation measures such as dose reduction,
delay, and growth factor use, if necessary. To accu-
rately evaluate the QALYs of the patients during the
chemotherapy period, it is necessary to model toxic-
ity dynamically instead of setting it constant during
the 6 months. However, the lack of the intermediate
toxicity data hinders such an attempt. To overcome
this problem, we used calibration, a commonly
used method in cancer simulation models,15–17 to esti-
mate the intermediate toxicity parameters using final
toxicity values (i.e., overall percentages of well (Pw)/
minor toxicity (Pmi)/major toxicity (Pma)/quitting adju-
vant chemotherapy (Pq)/death due to adjuvant chemo-
therapy (Pd)),
18 which is described in more detail in
the next subsection. During months 1 to 6, we modeled
the toxicity progression using the Markov model rep-
resenting the adjuvant chemotherapy period and
assumed that no patients relapse. This is justified
because relapse is unlikely at this point.
For the follow-up period model, we ignored the
differences between the relapse probability of
the patients in the chemotherapy groups and that of
the patients in the observation group after 5 years
due to limited data. More specifically, we assumed
that the relapse rate after year 5 is zero, and we calcu-
lated the life expectancy of the patients without relapse
at the end of the follow-up period using US Life
Tables.19 However, the patients who have relapsed
and are alive at the beginning of the sixth year continue
to be simulated in the follow-up model using respec-
tive mortality probabilities until they reach the death
state. Note that each patient has been simulated indi-








Free of Cancer Alive with Relapse Death
A B
Figure 1. Adjuvant chemotherapy and follow-up period models. (A) Incremental cost-effectiveness ratio (ICER) of FOLFOX as compared
with 5FU/LV. (B) ICER of 5FU/LV as compared with observation. 5FU/LV, 5-fluorouracil/leucovorin; FOLFOX, 5FU, leucovorin, and
oxaliplatin.
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Calibration Process
We denoted the transition probabilities of the adju-
vant chemotherapy model by Pw-w, Pw-mi, Pw-ma, Pmi-w,
Pmi-mi, Pmi-ma, Pma-w, Pma-mi, Pma-ma, Pma-q, and Pma-d,
where subscript w represents the well state, mi repre-
sents the minor toxicity state, ma represents the major
toxicity state, q represents quitting the adjuvant che-
motherapy state, and d represents death due to the
adjuvant chemotherapy state. For example, Pw-mi rep-
resents the probability that a patient who is in the well
state in the current month will move to the minor tox-
icity state in the next month. Among these probabili-
ties, we calculated Pw-w as 0.66 directly using the
following equation: Pw = (Pw-w),
6 where Pw is shown
in Table 1. We derived some other probabilities
(Pw-mi, Pmi-ma, and Pma-mi) directly as well—for exam-
ple, Pw-mi = 1 – Pw-w – Pw-ma. To estimate the remaining
parameters, we used a calibration method,16 which
proceeds as follows:
Step 1: We defined a plausible value range and a step
size for each probability parameter based on expert opin-
ion. For example, we set Pw-ma in [0.01, 0.1] and Pma-d in
[0, 0.04] with a step size of 0.01, Pmi-w in [0.30, 0.80],
Pmi-mi in [0.20, 0.50], Pma-w in [0, 0.30], Pma-ma in [0,
0.30], and Pma-q in [0, 0.20] with a step size of 0.02.
Step 2: Using each combination of these parameters, we
simulated the toxicity transition trajectories for a cohort
of 5000 patients. We classified each patient according to
his or her most advanced toxicity level. For example,
after 6 months, if the patient experienced well, minor
toxicity, and major toxicity, we classified her or him as
a patient with major toxicity. Then, for each parameter
combination, we calculated the corresponding values
from the output statistics—that is, overall percentages
of well (P0w), minor toxicity (P
0
mi), major toxicity (P
0
ma),
quitting adjuvant chemotherapy (P0q), and death due to
adjuvant chemotherapy (P0d), which are presented in
Table 1.
Step 3: For each combination of these parameters, we









q) with the actual data (Pma,
Pmi, Pw, Pd, and Pq; Table 1) by calculating the total
square error (TSE).14 We then selected the parameter
combination with the minimum TSE.
TSE 5 ðPma  P0maÞ
2
1 ðPmi  P0miÞ
2
1 ðPw  P0wÞ
2
1 ðPd  P0dÞ
2
1 ðPq  P0qÞ
2:
Our calibration process has generated the follow-
ing parameter values that are used in the adjuvant
chemotherapy period model: Pw-ma = 0.03, Pmi-w =
0.36, Pmi-mi = 0.32, Pma-w = 0.1, Pma-ma = 0.3, Pma-q =
0.2, and Pma-d = 0.01 for the FOLFOX regimen and
Pw-ma = 0.03, Pmi-w = 0.36, Pmi-mi = 0.32, Pma-w = 0.1,
Pma-ma = 0.3, Pma-q = 0.2, and Pma-d = 0.01 for the
5FU/LV regimen.
Base-Case Parameters
All parameters used in the base-case analysis,
including probabilities, utilities, and costs, are listed
in Tables 1 to 5.
Several clinical studies report on the incidence of
toxic effects due to 5FU/LV or FOLFOX.4,12,20 We
use the toxicity values reported in the MOSAIC trial
for both treatment arms, where we define the highest
incidence of toxicity events with a grade 3 or higher
grade as ‘‘major toxicity,’’ the remaining patients
with the incidence of any toxicities as ‘‘minor toxic-
ity,’’ and the patients with no gradable toxicity as
‘‘well.’’ Although the data used for estimation come
from a mixed cohort of stage II and stage III patients,
which may amplify the toxicity values for stage II
patients, overestimation of toxicity is preferable to
underestimation in this analysis in favor of conserva-
tive and reliable conclusions.
Table 1 Parameters Used for Calibration
Value, %
Parameters FOLFOX 5FU/LV Data Source
Overall toxicity after adjuvant chemotherapy
Percentage of major toxicity Pma 50.9 6.6 André and others, 2004
4
Percentage of minor toxicity Pmi 41.1 60.3
Percentage of well Pw 8.0 33.1
Percentage of death due to adjuvant chemotherapy Pd 0.5 0.5 de Gramont and others, 2007
36
Percentage of quitting adjuvant chemotherapy Pq 25.3 13.5 André and others, 2009
12
5FU/LV, 5-fluorouracil/leucovorin; FOLFOX, 5FU, leucovorin, and oxaliplatin.
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In the follow-up period, as the cancer relapse prob-
abilities were time dependent,21 we used an annual
transition probability from state 1 (free of cancer) to
state 2 (alive with relapse) instead of the stationary
transition probability for those 5 years. First, we esti-
mated the 1-year to 5-year relapse probabilities of the
observation group and chemotherapy groups with
FOLFOX and 5FU/LV using the Kaplan-Meier
relapse curve of the QUASAR trial7 and the Kaplan-
Meier disease-free survival (DFS) curve of the
MOSAIC trial,12 respectively. We assumed that ‘‘1 –
DFS’’ was equal to the relapse probability, which
was a conservative estimation for the impact of FOL-
FOX because it was slightly higher than the actual
relapse probability. We obtained the 5-year survival
probability of the observation group from the
Table 2 Probability Parameters
Toxicity after Adjuvant Chemotherapy Period Value, % Data Source
6 months after chemotherapy
André and others, 
20044
 Percentage of minor toxicity 39.7
 Percentage of major toxicity 1.3
18 months after chemotherapy
 Percentage of minor toxicity 23.2
 Percentage of major toxicity 0.5
Follow-up Period FOLFOX 5FU/LV Observation Data Source
Relapse and survival data 
 5-year relapse probability, % *16.3 ± 20 *20 ± 20 †24 ± 20
 1-year relapse probability, % *2 *4 †5.5 †QUASAR 
Collaborative Group, 
20077




O’Connell and others, 
200430
 2-year relapse probability, % *9 *11 †13
 3-year relapse probability, % *11.5 *14 †19
 4-year relapse probability, % *14 *18 †21
 5-year relapse probability, % *16.3 *20 †24
 5-year survival probability, % *87 (82–90) *87 (82–90) ‡80 (75–82)
Transition probability
  State 1 (free of cancer) to state 2  
  (alive with relapse)
  State 1 to state 2 in year 1 0.02 0.04 0.055  
Calculated from annual 
relapse probability 
from year 1 to year 5
  State 1 to state 2 in year 2 0.0714 0.0729 0.0794
  State 1 to state 2 in year 3 0.0275 0.0337 0.0690
  State 1 to state 2 in year 4 0.0282 0.0465 0.0247
  State 1 to state 2 in year 5 0.0267 0.0244 0.0380
  State 1 to state 2 > year 5 0 0 0 Assumed
  State 2 (alive with  







Calculated from annual 
relapse probability 
from year 1 to year 5 
and 5-year survival 
probability
 State 1 (free of cancer) to state 3 (death)
  State 1 to state 3 in year 1 0.009493
  State 1 to state 3 in year 2 0.010449
  State 1 to state 3 in year 3 0.011447 Arias, 200719
  State 1 to state 3 in year 4 0.012428
  State 1 to state 3 in year 5 0.013408
 Expectation of life at age 65 years 18.7
 Discount rate, % 3 (0–5)
5FU/LV, 5-fluorouracil/leucovorin; FOLFOX, 5FU, leucovorin, and oxaliplatin.
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QUASAR trial7 and the 5-year survival probability of
the chemotherapy groups from the 6-year survival
probability of the MOSAIC trial.12 Second, using
those data, we derived the annual transition probabil-
ities from state 1 to state 2 accordingly.22
For example, the 1-year and 2-year relapse proba-
bilities are 2% and 9%, respectively, for the FOLFOX
chemotherapy group. Then, the transition probability
from state 1 to 2 in year 1 under FOLFOX therapy
(P121 ) is easily computed as 0.02. The transition prob-
ability from state 1 to 2 in year 2 under FOLFOX ther-
apy is calculated as follows: (1 2 0.02) * P122 1 0.02
= 0.09, then P122 = 0.0714. Similar calculations hold
for the 5FU/LV therapy using respective parameters.
The transition probabilities from state 1 (free of
cancer) to state 3 (death) are obtained using US Life
Tables.19 The calculation of the transition probabilities
from state 2 (alive with relapse) to state 3 (death) pro-
ceeds as follows. Let x, y, and z represent the transition
probabilities from state 2 (alive with relapse) to state 3
(death) for the FOLFOX, 5FU/LV, and observation
groups, respectively. We assume that x, y, and z are
constant from years 1 to 5. Table 3 presents the compu-
tations to find x, y, and z. In Table 2, the 5-year death
probability is taken as 13% for the chemotherapy
groups since the 5-year survival probability is 87%,
as shown in Table 2. Similarly, the 5-year death prob-
ability for the observation group is 20%. Table 3 uses
the fact that summation of deaths through years 1 to
5 is equal to the 5-year death probability to calculate
x, y, and z.
We expressed all costs in 2007 US dollars. Two
separate studies reported the cost of FOLFOX and
5FU/LV as $29,000 and $6500 in 200723 and
Table 3 Calculation of Transition Probabilities from State 2 to 3
FOLFOX 5FU/LV Observation
Death in year 1 0.02x 0.04y 0.055z
Death in year 2 (0.09 2 0.02x)x (0.11 2 0.04y)y (0.13 2 0.055z)z
Death in year 3 (0.115 2 0.09x 1 0.02x2)x (0.14 2 0.11x 1 0.04y2)y (0.19 2 0.13z 1 0.055z2)z
Death in year 4 (0.14 2 0.115x
1 0.09x2 – 0.02x3)x
(0.18 2 0.14y
1 0.11y2 – 0.04y3>)y
(0.21 2 0.19z 1 0.13z2
– 0.055z3)z
Death in year 5 (0.163 2 0.14x 1 0.115x2
– 0.09x3 1 0.02x4)x
(0.2 2 0.18y 1 0.14y2
– 0.11y3 1 0.04y4)y
(0.24 2 0.21z 1 0.19z2
– 0.13z3 1 0.055z4)z
5-year death probability 0.13 0.13 0.20
Transition probability
from state 2 to 3a
x = 0.2978 y = 0.2252 z = 0.2935
5FU/LV, 5-fluorouracil/leucovorin; FOLFOX, 5FU, leucovorin, and oxaliplatin.
aTransition probability from relapse to death of all causes (disease-related and overall mortality).
Table 4 Costs and Ratio Parameters
FOLFOX 5FU/LV Observation Data Source
Adjuvant chemotherapy
period (620%)
$29,000 $6500 0 Aballéa and others, 200723
Adjuvant chemotherapy induced toxicity cost and ratio
Grades 3–4 neutropenia $132 ($118–$156) $132 ($118–$156) 0 Tumeh and others, 20093
Percentage of grade 3–4
neutropenia
41.1 4.7 0 André and others, 20044
Febrile neutropenia
(hospitalization)







0 *André and others, 20044
yKuebler and others, 200737
Grade 3–4 diarrhea $117 ($97–$137) $117 ($97–$137) 0 Tumeh and others, 20093






0 *André and others, 20044
yViele, 200338
Relapse cost (620%) $58,800 $61,200 $61,200 Aballéa and others, 200723
5FU/LV, 5-fluorouracil/leucovorin; FOLFOX, 5FU, leucovorin, and oxaliplatin.
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$34,628 and $765 in 2004,24 respectively. We chose
the most recent cost report for our base-case analysis.
Despite the fact that these cost figures are from 2007,
Medicare billing rates have been flat for these regi-
mens for the past 5 years and therefore are applicable
for the cost-effectiveness calculations. Note that we
included the most costly adverse effects in our analy-
sis and used the corresponding incidence rates for
cost calculations.
We use several studies to estimate the utility of
adjuvant chemotherapy for patients. An important
component for utilities is the utility of patients with-
out adjuvant chemotherapy. Considering the surgery
before chemotherapy, we applied a slightly lower
utility than a healthy individual25 to the ‘‘well’’ state
based on a study by Ramsey and Andersen,26 who
showed that patients without adjuvant chemother-
apy had a utility of 0.84. We used the same study to
estimate the utilities from year 2 through year 5. For
minor toxicity, we calculated the utility by comput-
ing the mean of the utilities of the patients with
mild (0.785) and moderate neuropathy (0.679) in
those receiving adjuvant chemotherapy. For major
toxicity, we used the average utility of patients with
severe neuropathy (0.585). On the other hand, we
set the utility of patients who are well between the
6th and 12th month of the chemotherapy group and
the first year of the observation group to 0.84, which
is the utility for the patients who are well during
chemotherapy.
Sensitivity Analysis
We also conducted an extensive sensitivity analy-
sis, in which we tested the effect of uncertainty in
clinically important parameters. We found the ranges
for the sensitivity analysis using available published
data, and otherwise we varied them within 20% of
the mean estimates, as shown in Tables 2, 4, and 5.
When the 5-year relapse probability varied, we
adjusted the 1-year to 5-year relapse probability using
the same distribution as shown in the base case.
Afterwards, we updated the transition probabilities
from state 1 (free from cancer) to 2 (alive with relapse)
and state 2 (alive with relapse) to 3 (death)
accordingly.
We ran our model for patients at different ages
between 50 and 80 years. We calculated age-based
ICER values assuming all parameters except the mor-
tality rates are kept constant. In addition to the above
analysis, we recalculated the ICER when nonmedical
costs, such as costs due to the workdays lost caused
by adjuvant chemotherapy, are included in the anal-
ysis. This is especially important for patients younger
than or equal to 65 years. Furthermore, we conducted
a probabilistic sensitivity analysis to address the
uncertainty around some of the parameters. Because
the available data for the uncertain parameters were
in the form a range with a midpoint or a most likely
value obtained from a large clinical study, we
assumed a triangular distribution around the uncer-
tain parameter values. We defined the base-case value
as the mode, the minimum value reported in the liter-
ature (or the lower bound) as the lower limit, and the
maximum value reported in the literature (or the
upper bound) as the upper limit of the triangular dis-
tribution, as shown in Tables 2, 4, and 5. We obtained
probabilities of cost-effectiveness by using common
random numbers when comparing the alternatives.
Although there is no absolute cost-effectiveness
threshold value, we used $50,000/QALY as a reference
value in this research. Note that the costs as mentioned
Table 5 Utility Parameters
Adjuvant chemotherapy period
Well 0.84 Ramsey and Andersen, 200026
Minor toxicity 0.73 (0.6–0.84) Best and others, 201039
Major toxicity 0.59 (0.49–0.68)
Alive with relapse (620%) 0.47 Camilleri-Brennan and Steele, 200140
Follow-up period
Sixth to 12th month for chemotherapy group 0.84 Ramsey and Andersen, 200026





65–74 years old 0.84 Fryback and others, 199341
75 years old 0.82 Fryback and Lawrence, 199725
65 years old 0.83 (0.84 1 0.82)/2
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in this study correspond to the prices, and therefore
the third-party payer’s perspective is taken.
RESULTS
In the base-case analysis, the patient receiving
adjuvant chemotherapy with the 5FU/LV regimen
gained 0.38 QALYs at a cost of $5542 as compared
with observation, and the patient receiving adjuvant
chemotherapy with the FOLFOX regimen gained
0.37 QALYs at a cost of $20,113 as compared with
the 5FU/LV regimen (Table 6). Consequently, the
ICER of adjuvant chemotherapy with FOLFOX was
54,359/QALY, and adjuvant chemotherapy with
5FU/LV was 14,584/QALY. In an analysis of life years
(LYs) saved, without quality weights, the adjuvant
chemotherapy with FOLFOX yielded 14.28 LYs,
5FU/LV yielded 13.90 LYs, and the observation
group yielded 13.34 LYs. Therefore, the ICER of adju-
vant chemotherapy with FOLFOX and 5FU/LV was
$52,929/LY and $9896/LY, respectively.
Figure 2 presents the tornado diagrams that sum-
marize the results of the 1-way sensitivity analysis
for parameters that significantly change the ICER val-
ues, where the vertical solid line represents the ICER
values under base case. The ICER values of FOLFOX
are most sensitive to the 5-year relapse probability,
cost of adjuvant chemotherapy, and the discount
rate, whereas the ICER values of 5FU/LV are most sen-
sitive to the 5-year relapse probability, 5-year survival
probability, and the relapse cost. The results are least
sensitive (not shown in the tornado diagram) to the
percentage of chemotherapy-induced toxicity and its
cost (grade 3–4 neutropenia, grade 3–4 febrile neutro-
penia [hospitalization], and grade 3–4 diarrhea).
Figure 3 displays the results of the sensitivity anal-
ysis for various ages, which shows that the ICER of
the adjuvant chemotherapy with FOLFOX as com-
pared with 5FU/LV increases exponentially with
age, especially when the patient is older than 65
years. The ICER of the adjuvant chemotherapy with
5FU/LV as compared with observation also increases
by age, but rather at a much smaller rate when com-
pared with the ICER of FOLFOX.
Next, we conducted a sensitivity analysis on cost
perspective such that the costs due to the workdays
lost caused by adjuvant chemotherapy are consid-
ered. Restricted by the limited data on the financial
impact of the toxicity of adjuvant chemotherapy, we
made a compromising assumption that all unretired
patients younger than or equal to 65 years did not
work during the full 6 months of adjuvant chemother-
apy at all. As the annual US average wage in 2003 was
$40,40527 and approximately 52.8%28 patients were
labor force participations when they were 60 years
old, the ICER increased to $42,655/QALY for 5FU/
LV. For patients who were 50 years old, 80.4%28 of
them were not retired, so the ICER increased from
$11,560/QALY to $45,399/QALY for 5FU/LV. The
unretired percentage of patients shrank sharply to
16%28 for people age 65 years or older, so the ICER
of 65-year-old patients increased from $17,234/
QALY to $27,336/QALY for 5FU/LV.
We also performed a probabilistic sensitivity
analysis for the uncertain parameters (Figure 4).
The probability of the cost-effectiveness of 5FU/LV
as compared with observation was 99.62% with
a $50,000/QALY threshold and 99.98% with
a $100,000/QALY threshold. On the other hand, the
probability of the cost-effectiveness of FOLFOX as com-
pared with the 5FU/LV was 44.48% with a $50,000/
QALY threshold and 97.24% with a $100,000/QALY
threshold. The mean of the ICERs was $55,697/QALY
and $16,136/QALY for FOLFOX and 5FU/LV,
respectively.
Table 6 Cost-Effectiveness Analysis of the Base Case (Discounting at 3%)
Base Case QALYs ICER
Chemotherapy group (FOLFOX) $35,271 11.65 $54,359/QALY
Chemotherapy group (5FU/LV) $15,158 11.28 $14,584/QALY
Observation group $9616 10.9
Without Adjustment for Quality of Life LYs ICER
Chemotherapy group (FOLFOX) $35,271 14.28 $52,929/LY
Chemotherapy group (5FU/LV) $15,158 13.90 $9896/LY
Observation group $9616 13.34
5FU/LV, 5-fluorouracil/leucovorin; FOLFOX, 5FU, leucovorin, and oxaliplatin; ICER, incremental cost-effectiveness ratio; LY, life year; QALY, quality-
adjusted life year.
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DISCUSSION
Compared with no postoperative treatment, adju-
vant chemotherapy with 5FU/LV for stage II colon
cancer achieves an ICER of $14,584/QALY, which is
cost-effective with respect to the benchmark of
$50,000/QALY. However, adjuvant chemotherapy
with FOLFOX for stage II colon cancer as compared
with 5FU/LV is less likely to be cost-effective, with
a base-case ICER of $54,359/QALY. It is also
Figure 2. Tornado diagram summarizing the results of the 1-way sensitivity analysis. 5FU/LV, 5-fluorouracil/leucovorin; FOLFOX, 5FU,
leucovorin, and oxaliplatin; QALY, quality-adjusted life year.
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reasonable to conclude that no matter whether the
costs due to lost workdays are considered, 5FU/LV
is cost-effective for people at all ages, whereas FOL-
FOX is cost-effective for patients younger than or
equal to 55 years only when the costs due to lost
workdays are not considered. The cost-effectiveness
ratio is most sensitive to 5-year relapse probability.
Because of the uncertainty around some of the param-
eters used in our models, we conducted a probabilis-
tic sensitivity analysis of these parameters. We found
that the ICER of 5FU/LV is less than $50,000/QALY
almost surely, and the ICER of FOLFOX as compared
with 5FU/LV is less than $50,000/QALY with
44.48% probability and less than $100,000/QALY
with 97.24% probability.
Because the data on the clinical utility of adjuvant
chemotherapy for stage II colon cancer continue to
evolve,29 a comparative cost-effectiveness analysis
of various adjuvant chemotherapy regimens may
appear to be premature. In fact, most studies focus
on trials comparing the effects of adjuvant chemother-
apy with observation instead of conducting a cost-
effectiveness analysis. Our analysis is important to
resolve whether the probable significant benefit due to
chemotherapy in stage II patients11 is justified in terms
of cost and toxicity. Previous studies noted that there
was probably a small benefit for adjuvant treatment of
stage II colon cancer, so the most important question is
whether this small benefit might prove to be clinically
significant for recommendation as standard therapy.
As a decision support tool, cost-effectiveness provides
a useful methodology to pursue the answer.
It is well known that not all stage II patients are
likely to benefit equally from the adjuvant chemo-
therapy.10 Patients with inadequate nodal sampling,
nearly or completely obstructing tumors, lymphovas-
cular invasion, or elevated carcinoembryonic antigen
are thought to be at higher risk of relapse. O’Connell
and others30 stated that according to the American
Joint Committee on Cancer staging guidelines (sixth
edition), the 5-year stage-specific survival is as fol-
lows: I (93.2%), IIa (84.7%), IIb (72.2%), IIIa
(83.4%), IIIb (64.1%), IIIc (44.3%), and IV (8.1%).
They argued that the 5-year survival of IIIa patients
is significantly higher than that of stage IIb patients,
which may be explained by current clinical practice
that stage III patients normally receive adjuvant che-
motherapy, but stage II patients generally do not. No
matter whether this conjecture is valid or not, those
data suggest that it is preferable to study IIa and IIb
separately. However, restricted by the limited data
for differentiating outcomes between stage IIa and
IIb and the effect of chemotherapy from the literature,
we did not stratify stage II colon cancer further.
Going forward, advances in understanding risk
stratification for stage II colon cancer may aid the
selection of who should receive adjuvant chemother-
apy. Genes predictive of varying risk of recurrence, as
well as sensitivity to 5FU-based chemotherapy
(microsatellite instability, chromosome 18q loss of
heterozygosity), have been identified and are in the
process of being more fully validated. The difference
in relapse-free survival between high- and low-risk
groups within stage II was about 15% to 18%. Assess-
ing risk at diagnosis would help in making the deci-
sion to undertake chemotherapy, as well as what
kind, more straightforward. Data presented at the
2009 and 2010 American Society of Clinical Oncology
Annual Meeting gave a window into risk stratification































Figure 3. Sensitivity analysis over age. 5FU/LV, 5-fluorouracil/
leucovorin; FOLFOX, 5FU, leucovorin, and oxaliplatin; ICER,





















Figure 4. Probabilistic sensitivity analysis. 5FU/LV, 5-fluoroura-
cil/leucovorin; FOLFOX, 5FU, leucovorin, and oxaliplatin; ICER,
incremental cost-effectiveness ratio; QALY, quality-adjusted life
year.
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DNA sequencing technologies exploring genes that
reflect tumor invasiveness and chemosensitivity.31–33
Using these tools may help risk stratify and gauge clin-
ical efficacy further, allowing for a more complete dis-
cussion of risk/benefit of chemotherapy.
Similarly, as more patients reach retirement age, it
is worth noting that the ICER of FOLFOX increases
dramatically with age, as other medical comorbidity
and death from noncancer causes factor into the
model. This cost-effectiveness analysis may help
decision making to restrict multiagent chemotherapy
to those patients who are most fit to receive chemo-
therapy and most likely to have expectations of non-
cancer survival that extend beyond 10 years.
As we await the results of intergroup trials (ECOG
5202) looking to answer the question of feasibility/
applicability of molecular markers in risk stratifica-
tion, the cost-effectiveness of adjuvant chemotherapy
can only be improved. Other trials under way look to
lessen the amount of chemotherapy delivered from 6
months to 3 months and perhaps decrease some of the
cumulative toxicity of oxaliplatin as well as the cost
of the drug by half.
Other regimens, including capecitabine, an oral
formulation of 5FU, have been developed over the
past decade. Capecitabine has the advantage of easier
delivery and less cost for administration but
increased cost of the drug. As we do not have the
same kind of direct comparison of efficacy between
capecitabine and FOLFOX in stage II disease, we
did not include it specifically in this analysis. There
is a body of literature to suggest that the efficacy is at
least noninferior in stage III colon cancer,34 and the
cost differential is minimal when including clinic
time and administration costs.35
Our conclusions are that it is likely to be cost-effec-
tive to consider 5FU/LV-based chemotherapy for
stage II colon cancer. The addition of a more toxic
and costly, but slightly more efficacious, chemother-
apy is less likely to be cost-effective. Examining com-
parative cost-effectiveness in an area where there is
continued clinical exploration and debate hopes to
make the discussion more focused on the clinical effi-
cacy than the concern for economic impact. Future
trials dedicated to stratifying risk and quantifying
benefit will be beneficial in future decision making
regarding adjuvant chemotherapy.
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